![Quiver Logo](/static/img/logo-icon.png)
![OCUP logo](https://quiver-logos.s3.us-east-2.amazonaws.com/ocup.png)
Ocuphire Pharma, Inc. Common Stock
Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Ocuphire's pipeline includes two small molecular product candidates targeting the front and back of the eye indications. The Nyxol candidate is being developed for dim light or night vision disturbances, reversal of pharmacologically induced mydriasis, and presbyopia. The second product candidate, APX3330, is being developed for diabetic retinopathy and diabetic macular edema.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view OCUP Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Recent trades of OCUP by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by OCUP's directors and management
Government lobbying spending instances
New patents grants
Federal grants, loans, and purchases
Recent insights relating to OCUP
Recent picks made for OCUP stock on CNBC
ETFs with the largest estimated holdings in OCUP
Flights by private jets registered to OCUP
![Quiver Logo](/static/img/logo-icon.png)